Lilly to File Retatrutide for Approval in Q1 2027 After 21% Weight Loss in Phase 3
LLY sits 89% above its 52-week low of $623.78.
Summary
Eli Lilly is preparing global regulatory submissions for retatrutide, its next-generation obesity drug, after two Phase 3 trials showed substantial weight loss. In type 2 diabetes patients, the 12mg dose delivered nearly 21% body weight reduction; in severe obesity with cardiovascular disease, patients lost 56 pounds on average. The company plans a U.S. submission as a biologic in Q1 2027, targeting obesity, knee osteoarthritis pain, and sleep apnea. This follows earlier Phase 3 readouts in May that first signaled retatrutide's potential, but today's announcement adds concrete efficacy figures and a clear regulatory timeline. Seeking biologic status is a strategic move to curb counterfeit versions and secure market exclusivity. With Zepbound and Mounjaro already driving exceptional revenue growth, retatrutide could extend Lilly's dominance in the obesity market. The drug's triple-hormone mechanism and strong safety profile position it as a potential best-in-class therapy.
At the time of this announcement, LLY was trading at $1,176.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.